2021 Fiscal Year Final Research Report
IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis
| Project/Area Number |
19K17676
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 予後予測マーカー |
|---|
| Outline of Final Research Achievements |
IL-18BP was more strongly expressed in the lungs of IPF patients than in healthy lungs, and serum IL-18BP levels in IPF patients was significantly higher than those in healthy subjects. In addition, IPF patients with high serum IL-18BP levels showed significantly poorer prognosis than patients with low serum IL-18BP, demonstrating that serum IL-18BP is useful as a novel prognostic biomarker for IPF.
|
| Free Research Field |
びまん性肺疾患
|
| Academic Significance and Societal Importance of the Research Achievements |
特発性肺線維症（Idiopathic pulmonary fibrosis: IPF）は慢性進行性の線維化を特徴とする間質性肺炎であり, 肺胞の不可逆的な破壊を来す. IPFの臨床経過は, 急速に進行する症例や緩徐に進行するものなど様々であり, 症例ごとに病勢の進行は異なる. このため、疾患進行や予後を予測しうるバイオマーカーはIPFの診療において必要不可欠であり、本研究の学術的意義は大きいと考える。
|
